Sanjay Bhutani – Country Manager, Bausch & Lomb India
Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He…
Address: Eli Lilly and Company (India) pvt. Ltd., Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA ,India
Tel: 91-124-4753000, 01
Web: https://www.lillyindia.co.in/
Eli Lilly and Company established its India operations in 1993 as a Joint venture with Ranbaxy Laboratories’ Limited. After the divestiture in 2001 it was Christened Eli Lilly and Company (India) Pvt. Ltd, and is today one of the most admired companies in terms of its focus on scientific selling, unique bouquet of products and services, working environment and focus on Ethics and Compliance Lilly India provides innovative answers to the needs of the people suffering from Diabetes, Cancer, Sepsis, Osteoporosis, Cardiovascular disorders and Growth hormone deficiency.
Major Achievements of Eli Lilly and Company (India) Pvt. Ltd.
In top 25 “Great Places to Work For in India” in 2003 and 2004 in a survey conducted by ‘Great Places to Work’ Institute
In top 25 in 2003 “Best Employers in India” in a survey conducted by Hewitt Associates.
2nd Best company to work for under ‘Biotech & Pharmaceutical’ category in 2008 in a survey conducted by Great Places to Work Institute USA’.
In top 10 “Best Companies to Work for in India’ in Business Today-Mercer-TNS survey 2008. Ranked 9th overall, achieving the unique distinction of being the only Pharmaceutical Company in this list.
We strive to touch the lives of our customers by actively listening and responding to their needs with breakthrough products and medical expertise that is critical to their understanding and treatment of diseases.
Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He…
Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse, Our greatest ability…
Dr Santosh Indraksha serves as Deputy Drugs Controller (India) for the Central Drugs Standard Control Organisation (CDSCO) under the Indian Ministry of Health and Family Welfare. As a representative of…
Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened…
Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights…
Drawing on a unique background in both medicine and law, Dr Milind Antani today leads the pharma and healthcare practice at Nishith Desai Associates, covering everything from regulatory work to…
J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management…
Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has…
Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal…
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
See our Cookie Privacy Policy Here
